Drug Topics

AUGUST 20, 2024

Bipartisan support—in a polarized Congress—underscores the importance of pharmacy benefit manager reform.

PharmaVoice

AUGUST 20, 2024

Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.

Drug Topics

AUGUST 20, 2024

Timothy Mackey, MAS, PhD, discusses the dangers associated with sourcing GLP-1s from illegal online pharmacies and the key role pharmacists play in warning patients.

Pharmacy Times

AUGUST 20, 2024

Palliative pharmacists are invaluable assets of oncologic care.

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

AUGUST 20, 2024

Final approval of the therapy may occur after expiration of the 3-year regulatory exclusivity for Tyvaso DPI on May 23, 2025.

FDA

STAT

AUGUST 20, 2024

Eli Lilly’s obesity drug Zepbound significantly cut the risk of developing type 2 diabetes, showing the benefits of long-term use of the blockbuster therapy. In a Phase 3 trial that lasted over three years, people with pre-diabetes taking Zepbound had a 93% lower risk of progressing to diabetes compared with people on placebo, Lilly said Tuesday.

STAT

AUGUST 20, 2024

A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal thoughts at a higher rate than people on other drugs, though experts raised concerns about the methodology and the findings contradict what some other studies have found about the class of GLP-1 diabetes and obesity drugs. Academic researchers analyzed a World Health Organization database that tracks suspected adverse drug reactions, and found that there was a 45% greater rate of reports of suic

Drug Topics

AUGUST 20, 2024

Inviting members of Congress into the pharmacy helps legislators experience first hand the value that pharmacists bring to their communities.

Fierce Healthcare

AUGUST 20, 2024

Health IT giant Epic is pushing ahead rapidly to build out artificial intelligence technologies and generative AI features in its electronic health record software. | The goal, according to Epic executives, is to ease the documentation burden for clinicians, streamline charting and coding and bring evidence-based medical insights and research right to doctors' fingertips at the point of care.

Documentation

STAT

AUGUST 20, 2024

The Food and Drug Administration’s responsibilities don’t end when a drug hits the market after it’s approved: the agency is also continuously assessing products after they’re widely available for any safety issues. And a group of researchers — including two from the FDA’s Center for Drug Evaluation and Research — think artificial intelligence could uncover more signs of these issues, including from electronic health records, social media posts, a

FDA

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Pharma

AUGUST 20, 2024

Regulators in both the U.S. and Europe have looked into the potential link between suicidal thoughts and Novo Nordisk’s blockbuster semaglutide franchise after reports sounded the alarm last year. | Researchers found that users of Novo's semaglutide who were logged in a WHO database were more likely to report suicidal ideation.

STAT

AUGUST 20, 2024

A House committee is investigating whether brand drug companies are collaborating with the Chinese military when they run clinical trials in that country.  “For over a decade, it appears that U.S. biopharmaceutical companies conducted clinical trials with China’s military organizations, and specifically with medical centers and hospitals affiliated with the People’s Liberation Army’s,” according to an Aug. 19 letter that the House China committee sent to t

Hospitals

Pharmacy Times

AUGUST 20, 2024

Jasmine Perry discusses the More Than a Script program in an interview with Pharmacy Times.

STAT

AUGUST 20, 2024

Science is a team sport, and those teams are getting larger. While that expansion might help researchers answer complex biomedical questions by working together, a recent study suggests that this trend has hampered the career prospects of Ph.D. graduates. The authors analyzed 40 years of data from a National Science Foundation survey that tracks Ph.D. graduates.

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Pharma

AUGUST 20, 2024

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. | As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem.

FDA

Pharmacy Times

AUGUST 20, 2024

The breakthrough therapy designation was granted based on ongoing data from the ARTEMIS-001 phase 1 open-label, multi-center trial.

Labelling

pharmaphorum

AUGUST 20, 2024

GSK gets FDA breakthrough status for its B7-H3 directed ADC, licensed from Hansah Pharma in a $1.

FDA

Pharmacy Times

AUGUST 20, 2024

Vimseltinib (Deciphera Pharmaceuticals) has a Prescription Drug User Fee Act goal date of February 17, 2025.

FDA

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Healthcare

AUGUST 20, 2024

The upward trajectory of Medicare Advantage (MA) enrollment is likely to become an issue for hospitals and other healthcare providers forced to contend with plans’ prior authorization requirements | Prior authorization burdens and "a challenging contract negotiation season" on the horizon are likely headwinds for providers, and hospitals in particular, according to a recent report.

Hospitals

Fierce Pharma

AUGUST 20, 2024

Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show. | Already wildly popular in type 2 diabetes and obesity, Eli Lilly’s tirzepatide can help prevent one of the very diseases it’s meant to treat, new data show.

Fierce Healthcare

AUGUST 20, 2024

Employers are up against escalating healthcare costs, driven by mounting prescription drug expenses, inflation and worsening chronic conditions, a new survey shows. | Employers are up against escalating healthcare costs, driven by mounting prescription drug expenses, inflation and worsening chronic conditions, a new survey shows.

Fierce Pharma

AUGUST 20, 2024

A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. | A new FDA approval has vaulted a Johnson & Johnson lung cancer drug combination into a key territory already dominated by AstraZeneca’s Tagrisso. But the real battle against the EGFR king has yet to start.

FDA

Fierce Healthcare

AUGUST 20, 2024

Below is a roundup of payer-centric news headlines you may have missed during the month of August 2024. | This month, Devoted Health completed its series E funding round, L.A. Care Health Plan slashed prior auth codes for catheter supplies, and Illinois signed laws cracking down on insurers involving colonoscopies, inhalers and more.

Insurance

Fierce Pharma

AUGUST 20, 2024

For years, Teva has been defending itself against allegations that it used illegal Medicare co-pay schemes to fuel sales of its multiple sclerosis drug Copaxone. | The new lawsuit, filed in a Kansas court, comes as Teva defends against similar allegations made by the U.S. government.

STAT

AUGUST 20, 2024

Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics and biosimilars — represent a system-critical industry that delivers around 80% of medicines used worldwide at a fraction of the cost of branded medicines.

FDA

pharmaphorum

AUGUST 20, 2024

Learn about the exciting potential of CDK9 inhibitors in disrupting cancer cell growth and changing the treatment landscape for cancer patients. Stay updated on the latest research and developments in this promising field.

STAT

AUGUST 20, 2024

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.  Sign up to get it  delivered in your inbox every Tuesday and Thursday. Carbon Health founder steps back from top role Carbon Health ‘ s chief executive and co-founder  Eren Bali is taking a step back from the primary care tech company, returning instead to the education company Udemy  he co-founded as its chief technology office

Hospitals

Pharmacy Times

AUGUST 20, 2024

The combination is the first and only multi-targeted chemotherapy-free regimen that demonstrated superiority compared with osimertinib for non–small cell lung cancer (NSCLC).

Chemotherapy

Fierce Healthcare

AUGUST 20, 2024

Amid significant scrutiny from lawmakers and regulators on Medicare Advantage, a new report suggests that consumer satisfaction with these plans is notably higher than with commercial insurance.

Insurance

pharmaphorum

AUGUST 20, 2024

Avidity Bio raises $345m from its second big public offering of 2024, after reporting encouraging Duchenne muscular dystrophy data.

Fierce Pharma

AUGUST 20, 2024

After picking up the European rights to Eli Lilly’s Emgality and Rayvow late last year, women’s health outfit Organon is upping its migraine accord with the Big Pharma company. | Organon has expanded a deal with Eli Lilly to become the sole promoter and distributor of Lilly’s migraine antibody Emgality in Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab Emirates.

pharmaphorum

AUGUST 20, 2024

Emergent BioSolutions has agreed to donate 50,000 doses of its mpox vaccine for use in the current outbreak, but an expert has warned supplies are unlikely to meet demand

Vaccines

PioneerRx

AUGUST 20, 2024

Chronic conditions make up the bulk of your pharmacy work. Patients with chronic conditions need certain medications for the rest of their lives to achieve a.